CFO Viktor Siewertz on dealmaking at BioStock Life Science Summit 2022

June 9, 2022

BioStock interviewed IRLAB Therapeutics’ CFO Viktor Siewertz about dealmaking, with special focus on IRLAB’s licensing deal with Ipsen in 2021. The interview was part of the event BioStock Life Science Summit 2022 held on June 8, 2022.

0:00 Introduction
0:53 Three key success factors for IRLAB’s deal with Ipsen
3:24 Importance of having an own R&D team
5:26 When to identify and approach potential takers
9:41 Negotiating the deal structure
13:22 How to spot a company likely to strike a deal?
15:00 Likelihood of IRLAB striking a second deal